Bugworks Research Secures $9 million in Series A Funding
A Bengaluru and Delaware-based drug discovery company called Bugworks Research has reportedly raised $9 million (about Rs 62.2 crore) in a Series A round of funding. This particular round was led by the University of Tokyo Edge Capital (UTEC).
The latest funding round also saw participation from South Africa-based Acquipharma Holdings, 3one4 Capital and angels including Marcus Schabacker, the former chief strategic officer of Baxter Healthcare, and Shrikumar Suryanarayan, former head of research and development at Biocon.
The funds so raised will be used by the company to deepen its clinical trials.
“The company, in three years, has invented a novel class of antibiotics for superbugs. We have completed several animal tests. The plan is to enter human trials by 2020,” said Anand An...